Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
Buy Rating Affirmed for Outlook Therapeutics Amid Strong Market Potential and Upcoming Milestones for ONS-5010/Lytenava
Express News | Outlook Therapeutics: Topline Results From Norse Eight Expected in Q4 Cy2024
Express News | Outlook Therapeutics Inc - Ons-5010 Bla Resubmission Planned for Q1 Cy2025
Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
Express News | Outlook Therapeutics® Announces Completion of Enrollment in Norse Eight Clinical Trial
Express News | Outlook Therapeutics Inc : Ascendiant Capital Markets Cuts Target Price to $33 From $35
Outlook Therapeutics Price Target Maintained With a $53.00/Share by Chardan Capital
Outlook Therapeutics Is Maintained at Buy by Chardan Capital
HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target
Outlook Therapeutics Analyst Ratings
H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright analyst Douglas Tsao maintains $Outlook Therapeutics(OTLK.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 41
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), Arrowhead Pharmaceuticals (ARWR) and Syndax Pharmaceuticals (SNDX)
Capital One Financial Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $25
Capital One Financial analyst Tim Chiang maintains $Outlook Therapeutics(OTLK.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate
Outlook Therapeutics | 10-Q: Q3 2024 Earnings Report
Outlook Therapeutics Poised for Growth: Strong Buy Recommendation Amidst Positive Clinical and Financial Developments
Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript Summary
Express News | Outlook Therapeutics Inc Q3 Shr View $-1.02 -- LSEG IBES Data
Express News | Outlook Therapeutics: Qtrly Shr Loss $0.89
Outlook Therapeutics Says Resubmission Of ONS-5010 Biologics License Application On Track For Q1 CY2025